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1. INTRODUCTION {#cam42740-sec-0005}
===============

Acute myeloid leukemia (AML) is a hematological neoplasm commonly seen in Taiwan and many other countries.[1](#cam42740-bib-0001){ref-type="ref"}, [2](#cam42740-bib-0002){ref-type="ref"} The estimated number of new cases was 21450 in the US in 2019.[2](#cam42740-bib-0002){ref-type="ref"} The median age of AML patients at diagnosis is about 70 years old.[3](#cam42740-bib-0003){ref-type="ref"} The median progression‐free survival (PFS) and overall survival (OS) of elderly AML patients (age ≥ 60) receiving standard induction treatment (7 + 3, cytarabine with an anthracycline) were 6.7 and 14.7 months, respectively.[4](#cam42740-bib-0004){ref-type="ref"} In elderly patients receiving hypomethylating agents (HMAs), the median PFS and OS were only 4.1 and 4.3 months, respectively. The high mortality in elderly AML patients was reported to be associated with old age, poor performance status, and disease characteristics such as high‐risk cytogenetics and complex karyotypes.[5](#cam42740-bib-0005){ref-type="ref"}, [6](#cam42740-bib-0006){ref-type="ref"}, [7](#cam42740-bib-0007){ref-type="ref"}, [8](#cam42740-bib-0008){ref-type="ref"}

Because the characteristics and outcomes of AML are very heterogeneous, several risk stratification systems have been developed. Malfuson et al reviewed 416 elderly patients treated in the ALFA‐9803 trial in France and identified high‐risk cytogenetics and the presence of at least two of the three factors (age ≥ 75, performance status ≥ 2, white blood cell (WBC) ≥50 × 10^9^/L) attributed to OS.[5](#cam42740-bib-0005){ref-type="ref"} Wheatley et al analyzed 2483 AML patients age ≥ 60 enrolled in two UK trials---the Medical Research Council AML11 Trial and the Leukaemia Research Fund AML14 Trial.[6](#cam42740-bib-0006){ref-type="ref"} They built up a risk score using cytogenetics, WBC, performance status, age, and AML type. Kantarjian et al found that intensive chemotherapy did not benefit most elderly AML patients (age ≥ 70). They identified age ≥ 80, complex karyotypes, poor performance and elevated creatinine \> 1.3 mg/dL as independent predictors for eight‐week mortality.[7](#cam42740-bib-0007){ref-type="ref"} Walter et al reviewed 2238 adults treated at MD Anderson Cancer Center and 1127 patients from 10 SWOG trials. They found that old age, poor performance status, and low platelet count were risk factors of early death after induction therapy for newly diagnosed AML.[8](#cam42740-bib-0008){ref-type="ref"} Ramos et al conducted a retrospective study (ALMA Registry) in Spain and developed the European ALMA score (using ECOG, WBC, and cytogenetics) to predict OS of unfit AML patients treated with an HMA.

The scoring systems mentioned above were developed in the US and European countries. They might not be suitable for predicting outcomes of our population due to differences in ethnicity and healthcare systems. We hence investigated risk factors for early mortality in elderly AML patients and aimed to develop a new scoring system, combining clinical data and genetic abnormalities, to predict outcomes of elderly AML patients in Asian populations.

2. MATERIALS AND METHODS {#cam42740-sec-0006}
========================

2.1. Study population {#cam42740-sec-0007}
---------------------

This study included consecutive elderly patients with newly diagnosed AML between 1 July 2008 and 31 May 2017 at Taipei Veterans General Hospital. Follow‐up was continued to 31 July 2017. AML was diagnosed based on WHO criteria,[9](#cam42740-bib-0009){ref-type="ref"} and bone marrow (BM) examinations were performed at diagnosis. Patients younger than 60 and those without a pathologic diagnosis were excluded.

2.2. Data collection and study endpoint {#cam42740-sec-0008}
---------------------------------------

Data collection was performed by reviewing medical records. The following clinical characteristics were obtained: age, sex, height, weight, and smoking status; comorbidities, including diabetes mellitus, hypertension, myocardial infarction, and ulcer diseases; laboratory parameters, including white blood cells with differential counts, hemoglobin, platelets, and blasts in peripheral blood and BM; performance status according to the Eastern Cooperative Oncology Group performance score (ECOG)[10](#cam42740-bib-0010){ref-type="ref"}, [11](#cam42740-bib-0011){ref-type="ref"}; genetic risk status, including cytogenetics and molecular abnormalities[12](#cam42740-bib-0012){ref-type="ref"}; which was recorded at diagnosis. Having an antecedent hematologic disorder was defined as having a history of specifically myelodysplastic syndromes, myeloproliferative neoplasms, or aplastic anemia.[13](#cam42740-bib-0013){ref-type="ref"} Cutoff values for age, performance status, WBC, platelet, cytogenetics, creatinine, and AML type were chosen according to those of the previous studies.[5](#cam42740-bib-0005){ref-type="ref"}, [6](#cam42740-bib-0006){ref-type="ref"}, [7](#cam42740-bib-0007){ref-type="ref"}, [8](#cam42740-bib-0008){ref-type="ref"}, [14](#cam42740-bib-0014){ref-type="ref"}, [15](#cam42740-bib-0015){ref-type="ref"}, [16](#cam42740-bib-0016){ref-type="ref"} The estimated glomerular filtration rate (eGFR) was calculated based on Chronic Kidney Disease Epidemiology Collaboration Equations[17](#cam42740-bib-0017){ref-type="ref"}, [18](#cam42740-bib-0018){ref-type="ref"}

Information on treatment regimens composed of induction and consolidation treatment was collected. Intensive treatment was defined as cytarabine with an anthracycline treatment or high‐dose cytarabine. Supportive care was defined as low‐dose cytarabine, hydroxyurea, or no AML‐specific treatment with blood transfusion.

Our primary endpoint was early mortality, defined as death within 60 days after AML initial diagnosis.[19](#cam42740-bib-0019){ref-type="ref"} Our retrospective review of medical records was conducted in accordance with the institutional ethics committee and in agreement with the Helsinki Declaration of 1975, revised in 2008. This study was approved by the Institutional Review Board at Taipei Veterans General Hospital (No. 2019‐05‐009BC).

2.3. Statistical analysis {#cam42740-sec-0009}
-------------------------

Patients' demographic and clinical characteristics were presented as the total number (*n*) and proportion (%) for categorical data, and medians and interquartile ranges (IQR) for continuous data (skewed).

Data for patients who did not have early mortality or who were lost to follow‐up were censored. In the survival analysis, the Kaplan‐Meier method was used for estimation of cumulative incidence of early mortality, and differences between groups were tested by log‐rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models, controlling for potential confounding factors in the multivariate model. We first used a univariate model to identify potential risk factors for AML early mortality. All risk factors with *P* \< .1 in the univariate model were further entered into the multivariate analysis. All independent risk factors identified in the multivariate analysis were then used to build a predictive model of early mortality.

The *β*‐coefficients of all significant risk factors in the multivariate Cox proportional hazards model were used to build a new risk‐scoring system. We also built a simplified score by assigning one point to each significant variable. Model discrimination was estimated by Harrell\'s C statistics. The discriminatory ability of our score and existing prognostic scores identified by a systematic review were compared using the Akaike information criterion (AIC) and Bayesian information criterion (BIC) calculations.

Data management and all statistical analysis were performed using SAS 9.4 software (SAS Institute Inc) and STATA statistical software, version 15.1 (StataCorp). All statistically significant levels were set at *P* \< .05.

3. RESULTS {#cam42740-sec-0010}
==========

3.1. Clinical characteristics of the study population {#cam42740-sec-0011}
-----------------------------------------------------

A total of 478 patients with newly diagnosed AML between 1 July 2008 and 31 May 2017 at Taipei Veterans General Hospital were identified. Patients who had no pathological confirmation (n = 5) and those diagnosed at age \< 60 (n = 196) were excluded. Finally, 277 elderly AML patients were enrolled in the study. The median age was 74 (range 60‐96), and 61.7% were men. Ninety‐four patients (33.9%) had secondary AML. Hypertension (45.9%) and diabetes mellitus (33.6%) were the most common comorbidities. In regards to cytogenetics and molecular abnormalities, 13.0%, 48.0%, and 33.9% had favorable, intermediate, and poor/adverse risk, respectively. The median of BM blasts was 80%, and 66.2% of the patients also had the presence of blasts in their peripheral blood. The initial treatment was categorized into cytarabine‐based intensive treatment, azacitidine or decitabine, all‐trans retinoic acid, and supportive care, which were 32.1%, 18.8%, 2.9%, and 46.2% of 277 patients, respectively (Table [1](#cam42740-tbl-0001){ref-type="table"}).

###### 

Baseline characteristics of elderly acute myeloid leukemia patients

+------------------------------------------+------------------------+
| Characteristics                          | Total                  |
|                                          |                        |
|                                          | n = 277                |
+==========================================+========================+
| Median age, years (range)                | 74 (60‐96)             |
+------------------------------------------+------------------------+
| ≥80                                      | 96 (34.7)              |
+------------------------------------------+------------------------+
| \<80                                     | 181 (65.3)             |
+------------------------------------------+------------------------+
| Secondary AML                            | 94 (33.9)              |
+------------------------------------------+------------------------+
| Therapy‐related AML                      | 25 (9.0)               |
+------------------------------------------+------------------------+
| Antecedent hematologic disorder          | 42 (15.2)              |
+------------------------------------------+------------------------+
| AML‐MRC                                  | 82 (29.6)              |
+------------------------------------------+------------------------+
| APL                                      | 11 (4.0)               |
+------------------------------------------+------------------------+
| Comorbidities                            |                        |
+------------------------------------------+------------------------+
| Diabetes mellitus                        | 93 (33.6)              |
+------------------------------------------+------------------------+
| Hypertension                             | 127 (45.9)             |
+------------------------------------------+------------------------+
| Myocardial infarction                    | 54 (19.5)              |
+------------------------------------------+------------------------+
| Ulcer disease                            | 45 (16.3)              |
+------------------------------------------+------------------------+
| ECOG                                     |                        |
+------------------------------------------+------------------------+
| 0‐1                                      | 154 (55.6)             |
+------------------------------------------+------------------------+
| ≥2                                       | 116 (41.9)             |
+------------------------------------------+------------------------+
| Unknown                                  | 7 (2.5)                |
+------------------------------------------+------------------------+
| Cytogenetics and molecular abnormalities |                        |
+------------------------------------------+------------------------+
| NPM1                                     | 20/125 (16.0)          |
+------------------------------------------+------------------------+
| FLT3‐ITD                                 | 18/125 (14.4)          |
+------------------------------------------+------------------------+
| Complex karyotype                        | 58/263 (22.1)          |
+------------------------------------------+------------------------+
| Cytogenetics and molecular risk status   |                        |
+------------------------------------------+------------------------+
| Favorable                                | 36 (13.0)              |
+------------------------------------------+------------------------+
| Intermediate                             | 133 (48.0)             |
+------------------------------------------+------------------------+
| Poor/adverse                             | 94 (33.9)              |
+------------------------------------------+------------------------+
| Unknown                                  | 14 (5.1)               |
+------------------------------------------+------------------------+
| Lab data, median (IQR)                   |                        |
+------------------------------------------+------------------------+
| Bone marrow blast, %                     | 80 (40‐90)             |
+------------------------------------------+------------------------+
| Presence of blasts in peripheral blood   | 182/275 (66.2)         |
+------------------------------------------+------------------------+
| White blood cell count,/uL               | 5830 (1890‐36 600)     |
+------------------------------------------+------------------------+
| Absolute neutrophil count,/uL            | 1254.4 (325.0‐5072.0)  |
+------------------------------------------+------------------------+
| Hemoglobin, g/dL                         | 8.4 (7.4‐9.5)          |
+------------------------------------------+------------------------+
| Platelets,/uL                            | 50 000 (26 000‐86 000) |
+------------------------------------------+------------------------+
| Creatinine, mg/dL                        | 1.0 (0.8‐1.4)          |
+------------------------------------------+------------------------+
| eGFR                                     | 65.2 (45.9‐82.8)       |
+------------------------------------------+------------------------+
| Initial treatment                        |                        |
+------------------------------------------+------------------------+
| Cytarabine‐based intensive treatment     | 89 (32.1)              |
+------------------------------------------+------------------------+
| Azacitidine or decitabine                | 52 (18.8)              |
+------------------------------------------+------------------------+
| All‐trans retinoic acid                  | 8 (2.9)                |
+------------------------------------------+------------------------+
| Supportive care                          | 128 (46.2)             |
+------------------------------------------+------------------------+

Abbreviations: AML, acute myeloid leukemia; AML‐MRC, acute myeloid leukemia with myelodysplasia‐related changes; APL, acute promyelocytic leukemia; ECOG, Eastern Cooperative Oncology Group performance; eGFR, estimated Glomerular filtration rate; IQR, interquartile range.
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3.2. Risk factors of early mortality {#cam42740-sec-0012}
------------------------------------

The median OS was 5.1 (95% CI 3.5‐6.4) months from diagnosis of AML. The probability of survival within 2 months was 70.1% (95% CI 64.1‐75.2%). The cumulative probability of the death curve is shown in Figure [1](#cam42740-fig-0001){ref-type="fig"}. In the univariate analysis, we found that age ≥ 80, having an antecedent hematologic disorder, myocardial infarction, ulcer diseases, ECOG performance status ≥ 2, complex karyotype, BM blasts ≥ 70%, WBC count ≥ 100 × 10^9^/L, and eGFR \< 45 were associated with early mortality in patients with AML (Table [2](#cam42740-tbl-0002){ref-type="table"}). In the multivariate analysis, age ≥ 80 (adjusted HR 1.88, 95% CI 1.08‐3.30), myocardial infarction (adjusted HR 1.87, 95% CI 1.08‐3.24), ECOG ≥ 2 (adjusted HR 2.10, 951.22‐3.63), complex karyotype (adjusted HR 3.21, 95% CI 1.80‐5.71), BM blasts ≥ 70% (adjusted HR 1.88, 95% CI 1.07‐3.32), WBC ≥ 100 × 10^9^/L (adjusted HR 3.31, 95% CI 1.59‐6.90), and eGFR \< 45 (adjusted HR 2.60, 95% CI 1.54‐4.39) remained statistically significant (Table [2](#cam42740-tbl-0002){ref-type="table"}).

![Overall survival of elderly patients with newly diagnosed acute myeloid leukemia](CAM4-9-1572-g001){#cam42740-fig-0001}

###### 

Risk factors for early mortality in elderly patients with newly diagnosed acute myeloid leukemia

  Predictive variables                                  n         No. of events   Univariate analysis   Multivariate analysis[a](#cam42740-note-0003){ref-type="fn"}                      
  ----------------------------------------------------- --------- --------------- --------------------- -------------------------------------------------------------- ------------------ --------
  Age ≥ 80                                              96        36              1.80 (1.16‐2.80)      .009                                                           1.88 (1.08‐3.30)   .027
  Sex (male)                                            171       52              1.20 (0.76‐1.91)      .436                                                                               
  Secondary AML                                         94        31              1.27 (0.81‐1.99)      .307                                                                               
  Therapy‐related AML                                   25        10              1.59 (0.82‐3.09)      .169                                                                               
  Antecedent hematologic disorder                       42        17              1.67 (0.98‐2.85)      .062                                                           1.78 (0.96‐3.30)   .066
  AML‐MRC                                               82        24              0.97 (0.60‐1.56)      .897                                                                               
  APL                                                   11        2               0.58 (0.14‐2.36)      .446                                                                               
  Comorbidities                                                                                                                                                                           
  Diabetes mellitus                                     93        23              0.80 (0.49‐1.30)      .370                                                                               
  Hypertension                                          127       38              1.10 (0.71‐1.72)      .660                                                                               
  Myocardial infarction                                 54        21              1.60 (0.97‐2.64)      .065                                                           1.87 (1.08‐3.24)   .025
  Ulcer disease                                         45        17              1.58 (0.92‐2.71)      .094                                                           1.21 (0.65‐2.24)   .553
  ECOG ≥ 2                                              116/270   46              2.73 (1.71‐4.38)      \<.001                                                         2.10 (1.22‐3.63)   .008
  Cytogenetics and molecular abnormalities                                                                                                                                                
  NPM1                                                  20/125    2               0.39 (0.09‐1.64)      .199                                                                               
  FLT3‐ITD                                              18/125    4               1.11 (0.39‐3.22)      .841                                                                               
  Complex karyotype                                     58/263    22              1.90 (1.15‐3.14)      .013                                                           3.21 (1.80‐5.71)   \<.001
  Cytogenetics and molecular risk                                                                                                                                                         
  Favorable                                             36/263    7               Reference                                                                                                
  Intermediate                                          133/263   36              1.44 (0.64‐3.25)      .374                                                                               
  Poor/adverse[b](#cam42740-note-0004){ref-type="fn"}   94/263    28              1.72 (0.75‐3.93)      .201                                                                               
  Lab data                                                                                                                                                                                
  Bone marrow blasts ≥ 70%                              157/263   50              1.65 (1.00‐2.73)      .049                                                           1.88 (1.07‐3.32)   .029
  Presence of blasts in peripheral blood                182/275   59              1.47 (0.89‐2.44)      .135                                                                               
  White blood cell count ≥ 100 K/µL                     26        15              3.19 (1.82‐5.62)      \<.001                                                         3.31 (1.59‐6.90)   .001
  Absolute neutrophil count \< 500/µL                   82        19              0.72 (0.43‐1.20)      .209                                                                               
  Hemoglobin \< 10 g/dL                                 231       63              0.76 (0.44‐1.31)      .320                                                                               
  Platelets \< 20 000/µL                                45        16              1.45 (0.84‐2.51)      .184                                                                               
  eGFR \< 45                                            63/274    30              2.71 (1.72‐4.28)      \<.001                                                         2.60 (1.54‐4.39)   \<.001

Abbreviations: AML, acute myeloid leukemia; AML‐MRC, acute myeloid leukemia with myelodysplasia‐related changes; APL, acute promyelocytic leukemia; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group performance; eGFR, estimated Glomerular filtration rate; HR, hazard ratio.

All factors with *P* \< .1 in the univariate analysis were included in the Cox multivariate analysis.

Poor/adverse risk was defined as complex (≥3 clonal chromosomal abnormalities), monosomal karyotype, −5, 5q‐, −7, 7q‐, 11q23 ‐ non t(9;11), inv(3), t(3;3), t(6;9), t(9;22), or FLT3‐ITD mutation with wild‐type NPM1.
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3.3. Risk stratification for elderly AML patients {#cam42740-sec-0013}
-------------------------------------------------

We built a prognostic model incorporating all independent risk factors. The *β*‐coefficients of all significant variables in the multivariate analysis were used to create the prognostic index for early mortality. The resulting equation is as follows:$$\begin{array}{ll}
{\text{Index}\,} & {= \, 0.63 \times \left\lbrack {\text{age} \geq 80} \right\rbrack + 0.63 \times \left\lbrack \text{myocardial\ infarction} \right\rbrack} \\
 & {\quad + 0.74 \times \left\lbrack {\text{ECOG} \geq 2} \right\rbrack + 1.16 \times \left\lbrack \text{complex\ karyotype} \right\rbrack} \\
 & {\quad + 0.63 \times \left\lbrack {\text{bone\ marrow\ blasts} \geq 70\%} \right\rbrack + 1.20} \\
 & {\quad \times \left\lbrack {\text{WBC\ count} \geq 100 \times 10^{9}/L} \right\rbrack + 0.96 \times \left\lbrack {\text{eGFR} < 45} \right\rbrack} \\
\end{array}$$

The median index in all participants was 1.4 (IQR 0.6‐2.3). Each increment in the index was associated with a nearly three‐times increase in hazard for early mortality (HR 2.70, 95% CI 2.06‐3.53). The prognostic index discriminated the risk of early mortality in elderly AML patients with an estimated Harrell\'s C statistic of 0.74 (95% CI 0.68‐0.81). A simpler risk model may be easier to use in clinical practice. Thus, we defined a simplified prognostic model by assigning one point for each of the seven independent predictors (age ≥ 80, myocardial infarction, ECOG ≥ 2, complex karyotype, BM blasts ≥ 70%, WBC ≥ 100 × 10^9^/L, and eGFR \< 45). Then we divided the patients into low‐risk (score 0‐1), intermediate‐risk (score 2‐3), and high‐risk (score 4‐5) groups, based on the scoring of the simplified model. The numbers of patients belonging to low‐, intermediate‐, and high‐risk groups were 91 (37.0%), 118 (48.0%), and 37 (15.0%), respectively (Table [3](#cam42740-tbl-0003){ref-type="table"}).

###### 

Incidence of early mortality in acute myeloid leukemia patients with risk scoring

  Risk score                                                     Level   n     No. of events      2‐mo mortality rate   HR (95% CI)        *P*‐value   AIC      BIC      Harrell C statistics
  -------------------------------------------------------------- ------- ----- ------------------ --------------------- ------------------ ----------- -------- -------- ----------------------
  Prognostic index[a](#cam42740-note-0006){ref-type="fn"}                246   64                 27.1 (21.8‐33.3)      2.70 (2.06‐3.53)   \<.001      624.82   626.97   0.74 (0.68‐0.81)
  Simplified risk score[b](#cam42740-note-0007){ref-type="fn"}   0‐1     91    9                  10.3 (5.5‐18.8)       Reference                      635.66   639.97   0.72 (0.66‐0.78)
  2‐3                                                            118     30    26.8 (19.4‐36.2)   3.01 (1.43‐6.33)      .004                                             
  4‐6                                                            37      25    70.7 (55.1‐84.8)   12.04 (5.60‐25.92)    \<.001                                           

Abbreviations: AIC, Akaike information criterion; BIC, Bayesian information criterion; CI, confidence interval; HR, hazard ratio.

Index = 0.63 × \[age ≥ 80\] + 0.63 × \[myocardial infarction\] + 0.74 × \[ECOG ≥ 2\] + 1.16 × \[complex karyotype\] + 0.63 × \[bone marrow blasts ≥ 70%\] + 1.20 × \[WBC count ≥ 100 × 10^9^/L\] + 0.96 × \[eGFR \< 45\].

Simplified risk score = \[age ≥ 80\] + \[myocardial infarction\] + \[ECOG ≥ 2\] + \[complex karyotype\] + \[bone marrow blasts ≥ 70%\] + \[WBC count ≥ 100 × 10^9^/L\] + \[eGFR \< 45\].
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The Kaplan‐Meier curves demonstrate that patients with higher scores had significantly shorter survival (log‐rank test *P* \< .001) (Figure [2](#cam42740-fig-0002){ref-type="fig"}). The HR for the intermediate‐ and high‐risk groups were 3.01 (95% CI 1.43‐6.33) and 12.04 (95% CI 5.60‐25.92), respectively, when compared with the low‐risk group. The predictive ability of the simplified model measured by Harrell\'s C statistic was 0.72 (95% CI 0.66‐0.78).

![Kaplan‐Meier estimates in acute myeloid leukemia patients stratified by risk scoring. We specified the risk strata by assigning one point for each of the seven factors (age ≥ 80, myocardial infarction, ECOG ≥ 2, complex karyotype, bone marrow blasts ≥ 70%, WBC count ≥ 100 K/µL, and eGFR \< 45) in a scoring system](CAM4-9-1572-g002){#cam42740-fig-0002}

3.4. Comparisons with different scoring systems {#cam42740-sec-0014}
-----------------------------------------------

We systematically reviewed existing prognostic models for elderly AML. We found five scoring models that do not require additional specific examinations and later applied them to our elderly AML cohort. Supplemental Table [2](#cam42740-tbl-0002){ref-type="table"} lists the performance of our model and the other five models. The median Malfuson index was 9.5 (IQR 5.8‐39.7). The index could not predict early mortality in our cohort.[5](#cam42740-bib-0005){ref-type="ref"} However, the simple decisional index had better performance (HR 3.03, 95% CI 1.72‐5.32 for score 1 and 3.19, 95% CI 1.49‐6.81 for score 2, respectively). The Wheatley index and its simplified risk score identified the poor‐risk group with a significant higher risk of early mortality (HR 3.43, 95% CI 1.47‐7.96 for index and HR 3.49, 95% CI 1.40‐8.71 for simplified risk score, respectively) although the probability of early mortality was similar between good and standard risk groups.[6](#cam42740-bib-0006){ref-type="ref"} Kantarjian\'s prognostic model divided the patients into four groups.[7](#cam42740-bib-0007){ref-type="ref"} The patients with two or ≥ three adverse factors had significantly high risk of early mortality (HR 3.35, 95% CI 1.53‐7.31 for score 2 and 7.08, 95% CI 3.22‐15.58 for score ≥ 3 adverse factors, respectively). Another two scoring models purposed by Ramos, Walter, et al predicted early mortality in the high‐risk group but had no significant difference between low‐ and intermediate‐risk groups.[8](#cam42740-bib-0008){ref-type="ref"}, [14](#cam42740-bib-0014){ref-type="ref"} Our prognostic model had the highest Harrell\'s C statistic and the lowest AIC and BIC compared with the other five prognostic models.

3.5. Causes of early mortality {#cam42740-sec-0015}
------------------------------

The direct causes of early death that occurred during this study are summarized in Figure [3](#cam42740-fig-0003){ref-type="fig"}. The most common cause was infection (49 patients, 62.0%). Prolonged neutropenia contributed to pneumonia, septic shock, and acute respiratory failure in patients who died early of infection. Five patients had ischemic strokes or intracranial hemorrhage; other bleeding causes included two patients with pulmonary hemorrhage and two patients with massive gastrointestinal bleeding. Acute renal failure occurred in nine patients, in which eight cases had acute kidney injuries and/or tumor lysis syndrome, and one case had central diabetes insipidus due to brain infiltration associated with acute leukemia cells. Cardiogenic shock occurred in four patients; three patients died of acute pulmonary edema without heart evaluation. Sudden death occurred in one patient at AML diagnosis. Four patients died at home or at other institutions and were without detailed information.

![Direct causes of early mortality. Infection, including pneumonia, bacteremia, and others; acute renal failure, etc, including acute renal failure, tumor lysis, or electrolyte imbalance; cardiogenic shock, etc, including cardiogenic shock or pulmonary edema](CAM4-9-1572-g003){#cam42740-fig-0003}

4. DISCUSSION {#cam42740-sec-0016}
=============

To the best of our knowledge, this is the first study that predicts early mortality of elderly AML patients in Asia and validates other prognostic models developed in Western countries. Based on the prognostic factors, we classified patients into three risk groups. The early mortality rate of low‐, intermediate‐, and high‐risk groups were 10.3%, 26.8%, and 70.7%, respectively. Our results may help physicians stratify patients and initiate proper treatment.

We have systematically reviewed existing AML prognostic scoring systems and evaluated the five prognostic models in our elderly AML cohort. Those AML risk‐stratified models used common risk factors, including age,[5](#cam42740-bib-0005){ref-type="ref"}, [6](#cam42740-bib-0006){ref-type="ref"}, [7](#cam42740-bib-0007){ref-type="ref"}, [8](#cam42740-bib-0008){ref-type="ref"} performance status,[6](#cam42740-bib-0006){ref-type="ref"}, [7](#cam42740-bib-0007){ref-type="ref"}, [8](#cam42740-bib-0008){ref-type="ref"}, [14](#cam42740-bib-0014){ref-type="ref"} WBC,[5](#cam42740-bib-0005){ref-type="ref"}, [6](#cam42740-bib-0006){ref-type="ref"}, [14](#cam42740-bib-0014){ref-type="ref"}, [15](#cam42740-bib-0015){ref-type="ref"} platelet,[8](#cam42740-bib-0008){ref-type="ref"} creatinine,[7](#cam42740-bib-0007){ref-type="ref"} BM blasts,[14](#cam42740-bib-0014){ref-type="ref"} cytogenetics,[5](#cam42740-bib-0005){ref-type="ref"}, [6](#cam42740-bib-0006){ref-type="ref"}, [7](#cam42740-bib-0007){ref-type="ref"} and types of AML.[6](#cam42740-bib-0006){ref-type="ref"} Our model consists of age, myocardial infarction, ECOG, complex karyotype, BM blasts, WBC, and eGFR, which are a part of routine workup for AML at diagnosis. Our model can easily be applied to AML patients in daily practice. In addition, our model had the highest C statistic and the lowest AIC and BIC, in comparison with other prognostic models.

We found that age is a key element of our model and some other models.[5](#cam42740-bib-0005){ref-type="ref"}, [6](#cam42740-bib-0006){ref-type="ref"}, [7](#cam42740-bib-0007){ref-type="ref"}, [8](#cam42740-bib-0008){ref-type="ref"} Elderly patients frequently have multiple comorbidities and have a lower probability of responding to induction treatment.[5](#cam42740-bib-0005){ref-type="ref"} Although our model has adjusted for some age‐associated adverse characteristics such as secondary AML and complex karyotypes, old age still negatively impacts patient outcomes.[6](#cam42740-bib-0006){ref-type="ref"} Kantarjian et al compared the outcomes of elderly AML patients stratified by age. They found age ≥80 years was an independent adverse prognostic factor for eight‐week mortality.[7](#cam42740-bib-0007){ref-type="ref"}, [20](#cam42740-bib-0020){ref-type="ref"} Farag et al reported that being age 80 or older doubled the risk of death for AML patients.[21](#cam42740-bib-0021){ref-type="ref"} Performance status is also an important element of disease prognosis, and it was included in all five existing prognostic models and our model. Poor performance status reflects organ dysfunctions.[16](#cam42740-bib-0016){ref-type="ref"}, [22](#cam42740-bib-0022){ref-type="ref"} Several studies show that poor performance status is the strongest predictor for OS and treatment‐related mortality.[5](#cam42740-bib-0005){ref-type="ref"}, [8](#cam42740-bib-0008){ref-type="ref"}

High WBC counts were associated with coagulopathy, pulmonary and CNS leukostasis, and renal failure.[20](#cam42740-bib-0020){ref-type="ref"}, [23](#cam42740-bib-0023){ref-type="ref"}, [24](#cam42740-bib-0024){ref-type="ref"}, [25](#cam42740-bib-0025){ref-type="ref"} Valcarcel et al found that leukocytosis (\>100 × 10^9^/L) doubled the risk of death during standard induction chemotherapy in newly diagnosed AML patients.[15](#cam42740-bib-0015){ref-type="ref"} A systemic review and meta‐analysis shows that early mortality related to hyperleukocytosis in AML is not reversed by leukapheresis or pharmacologic cytoreduction.[26](#cam42740-bib-0026){ref-type="ref"} Acute renal failure was a common cause of death in previous studies.[15](#cam42740-bib-0015){ref-type="ref"}, [26](#cam42740-bib-0026){ref-type="ref"}, [27](#cam42740-bib-0027){ref-type="ref"} Low creatinine clearance may increase the toxicity of chemotherapy and other medication.[28](#cam42740-bib-0028){ref-type="ref"} It also contributes to tumor lysis syndrome.[29](#cam42740-bib-0029){ref-type="ref"}, [30](#cam42740-bib-0030){ref-type="ref"}, [31](#cam42740-bib-0031){ref-type="ref"} Therefore, drug dose adjustment is needed in patients with renal impairment.[32](#cam42740-bib-0032){ref-type="ref"} In the current study, we use eGFR because creatinine differs by sex.[17](#cam42740-bib-0017){ref-type="ref"}, [18](#cam42740-bib-0018){ref-type="ref"} Myeloblasts in BM reflect disease burden. Farag et al found a 6% increase of mortality risk with every 1% increase of BM blasts. Complex karyotype is an unfavorable prognostic factor in AML patients. Many studies have shown that complex karyotype can predict a lower chance of achieving CR or post‐induction mortality in elderly AML patients.[7](#cam42740-bib-0007){ref-type="ref"}, [16](#cam42740-bib-0016){ref-type="ref"}, [21](#cam42740-bib-0021){ref-type="ref"} Therefore, elderly AML patients with unfavorable cytogenetics might not benefit from standard therapies.[33](#cam42740-bib-0033){ref-type="ref"} Myocardial infarction is a key prognostic factor for cancer patients.[34](#cam42740-bib-0034){ref-type="ref"} Anthracycline treatment might cause cardiomyopathy and heart failure.[35](#cam42740-bib-0035){ref-type="ref"} The patients with myocardial infarction received less intensive treatment in the current study.

A remarkable study from MD Anderson Cancer Center in 2010 revealed that intensive chemotherapy did not benefit most elderly AML patients.[7](#cam42740-bib-0007){ref-type="ref"} In the study, four of the variables (age, performance status, karyotype, and creatinine) in our model were used to predict the probability of early mortality after receiving intensive chemotherapy. The median survival of elderly AML patients with one, two, and ≥ three risk factors were only 5.3, 1.5, and 0.5 months, respectively. Therefore, they recommend elderly patients with any risk factor not receive intensive chemotherapy.

Our study has some limitations. Our patients did not receive new tests for molecular abnormalities, such as *ASXL1*, *TP53*, and *RUNX1*, which were recommended by the European LeukemiaNet guidelines in 2017.[12](#cam42740-bib-0012){ref-type="ref"} The choice of AML treatment was decided based on patient characteristics and was highly associated with all prognostic factors. Receiving supportive care might be a potential confounding factor in this study. Due to the retrospective nature of this study, our findings may be subject to selection bias, so further validations are warranted.

5. CONCLUSION {#cam42740-sec-0017}
=============

Early mortality in elderly AML patients is still common despite the development of novel therapies. It\'s crucial to find out the prognostic factors and plan management strategies according to disease risk stratification. Of great importance, we systemically reviewed all current prognostic models and include risk factors suitable for routine practice. We identified seven risk factors of early mortality, including age ≥ 80, myocardial infarction, ECOG ≥ 2, complex karyotype, BM blasts ≥ 70%, WBC ≥ 100 × 10^9^/L, and eGFR \< 45. Our findings may help clinicians stratify elderly AML patients and initiate appropriate treatment.
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